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Tetramethylpyrazine protects Schwann cells from ischemia-like 
injury and increases cell survival in cold ischemic rat nerves
Ming-Ming Yang, Wei Huang, Dian-Ming Jiang*
Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing,  
People’s Republic of China
Tetramethylpyrazine (TMP), a major active ingredient of Ligusticum wallichi Franchat extract (a Chinese 
herb), exhibits neuroprotective properties in ischemia. In this study, we assessed its protective effects on 
Schwann cells (SCs) by culturing them in the presence of oxygen glucose deprivation (OGD) conditions 
and measuring cell survival in cold ischemic rat nerves. In the OGD-induced ischemic injury model 
of SCs, we demonstrated that TMP treatment not only reduced OGD-induced cell viability losses, cell 
death, and apoptosis of SCs in a dose-dependent manner, and inhibited LDH release, but also suppressed 
OGD-induced downregulation of Bcl-2 and upregulation of Bax and caspase-3, as well as inhibited the 
consequent activation of caspase-3. In the cold ischemic nerve model, we found that prolonged cold 
ischemic exposure for four weeks was markedly associated with the absence of SCs, a decrease in cell 
viability, and apoptosis in preserved nerve segments incubated in University of Wisconsin solution 
(UWS) alone. However, TMP attenuated nerve segment damage by preserving SCs and antagonizing 
the decrease in nerve fiber viability and increase in TUNEL-positive cells in a dose-dependent manner. 
Collectively, our results indicate that TMP not only provides protective effects in an ischemia-like injury 
model of cultured rat SCs by regulating Bcl-2, Bax, and caspase-3, but also increases cell survival and 
suppresses apoptosis in the cold ischemic nerve model after prolonged ischemic exposure for four weeks. 
Therefore, TMP may be a novel and effective therapeutic strategy for preventing peripheral nervous 
system ischemic diseases and improving peripheral nerve storage.
Uniterms: Tetramethylpyrazine. Schwann cell. Oxygen glucose/deprivation. Peripheral nerve. Ischemia/
experimental study. University of Wisconsin solution.
Tetrametilpirazina (TMP), o principal componente do extrato de Ligusticum wallichi Franchat (erva 
chinesa), apresenta propriedades neuroprotetoras na isquemia. Nesse estudo, avaliamos seus efeitos 
protetores nas células de Schwann (SC), cultivando-as na presença de condições de depleção de oxigênio 
da glicose (OGD) e medindo a sobrevivência dos nervos de ratos isquêmicos pelo resfriamento. No 
modelo de lesão isquêmica em SC induzida por OGD, demonstramos que o tratamento com TMP não 
somente reduziu as perdas de viabilidade celular induzida por OGD, a morte celular, a apoptose de 
SC dose-dependente e inibiu a liberação de LDH, mas, também, suprimiu a infra-regulação do Vcl-2 
e a supra-regulação de Bax e caspase-3, e inibiu a consequente ativação da caspase-3. No modelo de 
nervo isquêmico por resfriamento, observamos que a exposição prolongada ao resfriamento por quatro 
semanas estava, marcadamente, associada com a ausência de SC, com o decréscimo da viabilidade 
celular e a apoptose em segmentos de nervo incubados na solução da Universidade de Wisconsin apenas. 
Entretanto, a TMP atenuou o dano no segmento do nervo preservando SC e antagonizando a diminuição 
da viabilidade da fibra nervosa e o aumento das células TUNEL-positiva de modo dose-dependente. De 
forma conjunta, nossos resultados indicam que o TMP não só fornece efeitos protetores em um modelo 
de dano semelhante à isquemia de SC de ratos cultivados pela regulação de BCl-2, Bax e caspase 3, mas, 
também, aumenta a sobrevivência celular e suprime a apoptose no modelo de isquemia por resfriamento 
por exposição prolongada por quatro semanas. Então, TMP pode ser uma estratégia terapêutica eficaz para 
prevenir doenças isquêmicas do sistema nervoso periférico e melhora a armazenagem do nervo periférico.
Unitermos: Tetrametilpirazina. Célula de Schwann. Oxigênio da glicose/depleção. Nervo periférico. 
Isquemia/tratamento/estudo experimental. Solução da Universidade de Wisconsin.
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INTRODUCTION
Nerve autografts have remained the gold standard 
for peripheral nerve gap repair for over 50 years. However, 
peripheral nerve injuries with extensive nerve deficits 
are still a challenge to reconstructive surgeons, which is 
compounded by limited amount of expendable nerves 
available for autografts and the inevitable and concomitant 
donor site morbidity that is associated with harvesting 
autografts. Tubulization techniques, including biological 
conduits (artery (Itoh et al., 1996) or vein (Chiu et al., 
1982)) and artificial conduits (silicone or polyglycolic 
acid polymer), are only feasible for repairing short nerve 
gaps (Mackinnon, 1989; Siemionow, Brzezicki, 2009). 
Advancements in our understanding of alloimmunity have 
resulted in a renewed interest in nerve allografts, which are 
now considered to be an available option for massive nerve 
tissue loss and a useful alternative to nerve autografts. 
The first description of the use of human peripheral nerve 
allografts provided encouraging results (Mackinnon, 
Hudson, 1992). However, peripheral nerve allograft 
transplantation requires tissue typing of both the donor and 
the recipient, and often transportation of graft materials 
over long distances. These preoperative requirements can 
result in variable storage times and conditions between 
the time of harvesting of the graft from the organ donor 
and implantation into the host. If an optimal storage 
method can be developed whereby peripheral nerves can 
be preserved for a sufficient amount of time for transport, 
then nerve allografts would be the first choice in peripheral 
nerve injury reconstruction. Ideally, the preservation of 
peripheral nerve grafts would result in the establishment 
of a nerve tissue bank.
The maintenance of Schwann cell (SC) viability 
in peripheral nerves during cold storage appears to 
be an important determinant in the successful repair 
of massive nerve deficits. SCs are the major cellular 
component of peripheral nerves and are vital in the 
axonal regeneration process. It has been reported that 
acellular nerve grafts generally fail to support axonal 
regeneration beyond 3cm (Hess et al., 2007). Ideally, 
the ability to successfully preserve nerve grafts prior 
to transplantation would ensure that the time needed to 
meet preoperative requirements would not jeopardize the 
viability of the grafts.
University of Wisconsin solution (UWS) is 
commonly used for flushing and cold storage of solid 
organs. This well-established cold storage medium has 
also been used for preserving segments of peripheral 
nerves, but it was shown that peripheral nerve segments 
stored in UWS over a long period of time (≥3 weeks) 
resulted in nerves with few viable SCs that were essentially 
acellular conduits (Levi et al., 1994). Ischemic injury 
may be partly responsible for the decrease in viable SCs, 
because it can initiate a cascade of events that results in cell 
death by apoptosis and necrosis (Faubel, Edelstein, 2005).
Tetramethylpyrazine (TMP), one of the major and 
most important active ingredients of traditional Chinese 
medicine Ligusticum wallichii Franchat (Chuan Xiong), 
has been used to treat ischemic disorders for many years 
(Chun-Sheng et al., 1978; Ho, Wen, Lee, 1989). However, 
limited data exist on the protective effect of TMP on 
ischemia-like injury of SCs, and no reports have described 
the use of a TMP solution for nerve tissue preservation. 
In this study, we examined the protective effects of TMP 
in an oxygen glucose deprivation (OGD)-induced SCs 
injury model, and explored the possible mechanism for 
the observations (Study 1). In addition, we hypothesized 
that TMP may increase cell survival in a cold ischemic 
rat nerve model after prolonged ischemia exposure of up 
to four weeks (Study 2), which would improve peripheral 
nerve storage, allow longer periods of preservation, and 
aid in peripheral nerve allotransplantation clinically 
available.
MATERIAL AND METHODS
All animal care procedures complied with the 
guidelines of the Chongqing Medical University Animal 
Care and Use Committee and the study was approved by 
the ethics committee of Chongqing Medical University.
Chemicals and reagents
TMP (purity >98%), dimethylsulfoxide (DMSO), 
collagenase, trypsin, basic fibroblast growth factor 
(bFGF), cytosine arabinoside, and 3-[4, 5-dimethylthiazol-
2-yl]-2,5-diphenyl-ltetrazolium bromide (MTT) were 
obtained from Sigma (St. Louis, MO, USA). The LIVE/
DEAD Viability/Cytotoxicity Kit was purchased from 
Molecular Probes (Eugene, OR, USA). The lactate 
dehydrogenase (LDH) assay kit was purchased from the 
Nanjing Jiancheng Bioengineering Institute (Nanjing, 
China). The Annexin V-FITC and propidium iodide (PI) 
apoptosis detection kits were obtained from KeyGen 
Biotech (JiangSu, China). Antibodies against S-100, Bax, 
Bcl-2, and β-actin, as well as a horseradish peroxidase 
(HRP) conjugated secondary antibody were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
The antibody against caspase-3 was obtained from Cell 
Signaling Technology (Beverly, Ma, USA). Dulbecco’s 
modified Eagle’s medium (DMEM) and fetal bovine 
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serum (FBS) were purchased from Gibco (Grand Island, 
NY, USA). University of Wisconsin solution (UWS) was 
obtained from Bristol-Myers Squibb Company (Princeton, 
New Jersey, USA).
Study 1
Schwann cell cultures
SC cultures were obtained using the method 
described in Brockes et al., 1980, with minor modifications. 
Briefly, sciatic nerves from 2-3-day-old Sprague-Dawley 
rats were harvested and digested with 0.1% collagenase 
and 0.25% trypsin at 37 °C for 15 min. Twenty-four 
hours after planting, the cells were treated with cytosine 
arabinoside for 48 h to eliminate proliferating fibroblasts. 
Following this treatment, the culture medium was replaced 
with fresh medium supplemented with 20 ng/mL bFGF 
to allow for SC proliferation. After eight days, the SCs 
were detached with 0.1% EDTA-trypsin and passaged. 
The culture medium was changed three times per week. 
Cultured cells were fixed with 4% paraformaldehyde 
and the purity of SCs was assessed by immunochemical 
staining of S-100 protein.
Oxygen glucose deprivation (OGD)
OGD was induced according to the method 
described by Keihoff et al., 2008. To initiate OGD, the 
original cell culture medium was removed and cells were 
gently washed with a glucose-free phosphate-buffered 
saline (PBS). Cells were then incubated in a fresh glucose-
free salt buffer solution containing 109.5 mM NaCl, 5.4 
mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 25 mM HEPES 
25, and 0.91 mM NaH2PO4. The cells were maintained in 
a hypoxic environment in a tri-gas cell culture incubator 
(Thermo Fisher Scientific, Basingstoke, UK) flushed 
with 5% CO2 and 95% N2 for 6 h followed by 1 h of 
reoxygenation in a standard incubator with 5% CO2. The 
concentration of oxygen, which was lower than 1%, was 
determined by an oxygen analyzer (Vascular Technology, 
NH, USA). TMP was freshly prepared as a stock solution 
with dimethylsulfoxide (DMSO) and diluted with PBS 
(pH 7.3). The final concentration of DMSO added to the 
cells never exceeded 0.1%. A 0.1% solution of DMSO, 
which was the highest concentration in the medium, was 
used as a vehicle control. TMP (0, 25, 50, 100 or 200 μg/
mL) was added to the culture at the start of OGD exposure 
and continued until the SC cultures were collected and 
analyzed. Normal control cultures were always maintained 
in normal medium under normal incubation conditions. 
The second passage of SCs were exposed to OGD and 
treated with TMP, and cells at 80% confluence were used 
for all experiments. Three replicates were used for each 
experiment.
Cell viability analysis
Cell viability was evaluated by two methods: 
an MTT assay and calcein-AM/ethidium homodimer 
I (EthD-I) staining. For the MTT assay, the MTT 
solution (20μl) in PBS was added to each well at a final 
concentration of 5 mg/mL and then incubated for an 
additional 4 h at 37 °C. The medium containing MTT was 
then removed and the blue MTT-formazan complex was 
dissolved in DMSO (100 μL). Optical density (OD) values 
were measured on a microplate reader at a wavelength of 
570 nm. Cell viability rates were expressed as the mean 
percentage of values of normal control cells.
A LIVE/DEAD Viability/Cytotoxicity Kit was also 
used to measure cell viability, which takes advantage of the 
phenomenon that living cells are able to hydrolyze calcein-
AM (2 µM) by intracellular esterases resulting in green 
fluorescence. In parallel, dead cells were labeled with 
ethidium homodimer I (EthD-I, 4 µM), which interacts 
with nucleic acids to yield a red fluorescence in cell nuclei. 
Each reagent was incubated with the cells for 30 min and 
then assessed on a fluorescence microscope.
LDH release assay
Cell cytotoxicity was quantitatively assessed 
by measuring the amount of LDH released from the 
damaged cells into the culture medium. LDH release into 
the culture medium was detected using a cytotoxicity 
detection kit according to the manufacturer’s instructions. 
Cultures under normal conditions (normal control 
group) represented basal LDH release, and the data were 
expressed as the mean percent of the maximal LDH 
released in the OGD alone group.
Analysis of apoptosis by flow cytometry
Apoptosis was measured by annexin V-FITC/PI 
staining and flow cytometry. Briefly, cells were harvested 
after the treatment and resuspended in PBS at a density of 
106 cells/mL). Aliquots of 105 cells were stained with 5 μL 
of annexin V-FITC and 10 μL of PI for 15 min at room 
temperature in the dark. The apoptosis rates were then 
quantified with a FACS Vantage SE flow cytometer (BD 
Biosciences, San Jose, Calif., USA). The cell populations 
of annexin V+/PI− and annexin V+/PI+ were calculated as 
a representation of apoptotic cells.
Real-Time PCR analysis
Total RNA was isolated from SCs by extraction 
with Trizol (Invitrogen) according to the manufacturer’s 
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instructions, and the RNA concentration was measured 
by ultraviolet spectroscopy. Primers were designed and 
synthesized by Shanghai Sangon (Shanghai, China), with 
β-actin used as an endogenous control for gene expression 
analysis. The primer sequences were as follows: Bax 
forward, 5’-ATG GCT GGG GAG ACA CCT GA-3’; Bax 
reverse, 5’-GCA AAG TAG AAG AGG GCA ACC-3’; 
Bcl-2 forward, 5’-CCT TCT TTG AGT TCG GTG-3’; 
Bcl-2 reverse, 5’-GAG ACA GCC AGG AGA AAT-3’; 
Caspase-3 forward, 5’-ATG CTT ACT CTA CCG CAC 
CCG-3’; Caspase-3 reverse, 5’-GGT TAA CAC GAG 
TGA GGA TGT GC-3’; β-actin forward, 5’-CGT TGA 
CAT CCG TAA AGA CCT C-3’; and β-actin reverse, 5’-
TAG GAG CCA GGG CAG TAA TCT-3’. Quantitative 
real-time PCR was performed using the SYBRTM Green 
real-time PCR Master Mix kit (TaKaRa, Japan) according 
to the manufacturer’s instructions, on a SLAN® Real-Time 
PCR Detection System (Hongshi Medical Technology 
Co., Ltd, Shanghai, China). The PCR cycling conditions 
were as follows: 95 °C for 1 min, followed by 40 cycles 
of denaturation at 95 °C for 15 s, annealing at 58 °C for 
20 s, and extension at 72 °C for 20 s. The relative transcript 
amount of target gene was normalized to that of β-actin 
using the 2-ΔΔct method, as previously described (Livak, 
Schmittgen, 2001).
Western blot analysis
SCs (1.0×106) from the different treatment groups 
were lysed in 200 μL lysis buffer (Beyotime Institute 
of Biotechnology, JiangSu, China) containing 100 mM 
phenylmethylsulfonyl fluoride (PMSF; Sigma) on ice 
for 30 min and then centrifuged at 14,000 x g for 10 min 
at 4 °C. Protein quantification was performed with the 
Bradford reagent (Beyotime Institute of Biotechnology, 
JiangSu, China). Protein samples were boiled for 10 min 
with loading buffer and then separated on 12% SDS-
PAGE gels. Each lane was loaded with 40 μg protein. 
After separation, the proteins were transferred to 
polyvinylidene fluoride (PVDF) membranes (Millipore, 
USA), and the membranes were blocked in 0.05% 
Tween-20 in TBS (TBS-T) containing 5% nonfat milk 
for 1 h. The membranes were then incubated overnight 
with antibodies to Bax (1:200 dilution), Bcl-2 (1:200 
dilution), and caspase-3 (1:1000 dilution), followed by 
incubation with the respective HRP-conjugated secondary 
antibodies (1:2000 dilution). In addition, β-actin (1:1000 
dilution) was used as a loading control to normalize the 
samples. Immunoblots were developed by enhanced 
chemiluminescence (ECL) (Pierce, USA). Quantitative 
analysis of the visualized protein bands was performed 
using an AlphaEaseFC imaging system (Alpha Innotech).
Study 2
Harvesting and preserving nerve grafts
Forty-two adult male Sprague-Dawley rats weighing 
200-250g were deeply anesthetized by an intraperitoneal 
injection of chloral hydrate (300mg/kg). Both sciatic 
nerves were removed under sterile technique using a 
muscle splitting incision. The nerve was transected 
proximally at the sciatic notch and distally at the point of 
trifurcation to harvest a 15 mm nerve graft segment. After 
the bilateral sciatic nerves were excised, the animals were 
sacrificed by cervical dislocation while still anesthetized. 
The nerve segments (n=84) were divided randomly into 
six equal groups:
·	 Fresh-nerve group (n=14): Nerve segments were 
removed without any storage.
·	 100 mg/mL TMP-nerve group (n=14): Nerve seg-
ments were immersed in UWS containing TMP 
(100 mg/mL) for 4 weeks at 4 °C.
·	 200 mg/mL TMP-nerve group (n=14): Nerve seg-
ments were immersed in UWS containing TMP 
(200 mg/mL) for 4 weeks at 4 °C.
·	 300 mg/mL TMP-nerve group (n=14): Nerve seg-
ments were immersed in UWS containing TMP 
(300 mg/mL) for 4 weeks at 4 °C.
·	 400 mg/mL TMP-nerve group (n=14): Nerve seg-
ments were immersed in UWS containing TMP 
(400 mg/mL) for 4 weeks at 4 °C.
·	 UW-nerve group (n=14): Nerve segments were im-
mersed in UWS containing 0.1% DMSO for 4 weeks 
at 4 °C.
TMP was freshly prepared as a stock solution with 
DMSO. Importantly, the final concentration of DMSO 
added to UWS never exceeded 0.1%. UWS was prepared 
immediately before nerve harvesting with the following 
additives: 200000 U/L penicillin G, 40 U/L humulin, and 
16 mg/L dexamethasone.
Electron microscopy
Three nerve segments from each study group were 
fixed in 3% (v/v) phosphate-buffered glutaraldehyde 
solution, post-fixed with 1% (w/v) phosphate-buffered 
osmic acid, and finally embedded in epoxy resin. Ultrathin 
sections of the nerve segments were stained with 5% (w/v) 
uranyl acetate in 70% methanol and lead citrate, dried, and 
then examined using transmission electron microscopy 
(TEM; Hitachi H-7500, Japan).
Assessment of nerve viability
Nerve viability was assessed by the method 
described by Matsumoto et al. (2005). Six nerve segments 
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of each study group were directly stained with a calcein-
AM/EthD-I stain (Live/Dead Viability/Cytotoxity Kit) to 
investigate the viability of the cells of the nerve segments 
as described above for the SCs.
TUNEL staining
For the TUNEL assay, five nerve segments from 
each study group were fixed in freshly prepared 4% 
paraformaldehyde-PBS solution, embedded in paraffin, 
and then cut in 5 µm thick sections. The nerve tissue 
section was stained using an in situ apoptosis detection kit 
according to the manufacturer’s instructions (Roche, SUI). 
The total number of TUNEL-positive cells was counted 
in five random microscopic fields (original magnification 
400x) from each section. Data were expressed as the 
number of TUNEL-positive cells per field.
Statistical analysis
Experimental data were analyzed using the statistical 
software package SPSS 16.0 (IBM, USA). All data were 
presented as mean±standard deviations (SD). Statistical 
differences among multiple groups were evaluated by 
one-way analysis of variance (ANOVA) followed by the 
least significant difference multiple-comparisons test as 
appropriate. A P-value < 0.05 was considered statistically 
significant.
RESULTS
Study 1
Primary cultured SCs with high purity
To assess the purity of the culture, we used a rabbit 
polyclonal antibody raised against S-100 to immunostain 
primary cultured SCs. S-100, which is a specific SC 
marker, is a calcium-binding protein. Cultures were stained 
with an anti-S-100 antibody to mark the SCs (green), and 
all cells showed Hoechst 33342 nuclear labeling (blue). 
The merged images from confocal fluorescence imaging, 
and the blue nuclei that overlapped with the green cell 
bodies were identified as SCs, while other cells present in 
the cultures were fibroblasts. Approximately 90% of the 
cells in the primary culture were verified as SCs (Figure 1).
Protective effects of TMP on SCs against OGD 
induced injury
We found that OGD induced substantial cell 
injury, as indicated by the MTT assay and calcein-AM/
EthD-I staining. As shown in Figure 2, SC viability was 
markedly decreased after the cells were exposed to OGD. 
FIGURE 1 - Immunohistochemistry of primary cultured SCs. 
The S-100 positive cells (green) represent SCs, and all cells 
showed Hoechst 33342 nuclear labeling (blue). Scale bar: 
200 μm.
FIGURE 2 - MTT assay. The effects of TMP on SC viability 
subjected to OGD were assessed with the MTT reduction test. 
Data are expressed as the mean percentage of values of the 
normal control group. Values are expressed as mean ± standard 
deviation (SD). *P < 0.05 vs. normal control group. #P < 0.05 vs. 
cells exposed to OGD alone. &P < 0.05 vs. 50 μg/mL TMP group.
The viability of the OGD alone group and vehicle control 
group (20.22±2.34 and 18.62±3.22%, respectively) was 
significantly lower than the normal control group (both 
P<0.01). In addition, the difference between the OGD 
alone group and vehicle control group was not statistically 
significant (P>0.05), which indicated that the vehicle 
(0.1% DMSO) had no additional deleterious effect on the 
viability of SCs. When the cells were treated with 50, 100, 
or 200 μg/mL TMP, the OGD-induced cell toxicity was 
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significantly attenuated in a TMP dose-dependent manner, 
and cell viabilities increased to 39.70±3.70, 50.41±4.80, 
and 50.09±5.97%, respectively, compared to the OGD alone 
group (all P<0.05). However, treatment with 25 μg/mL 
TMP provided no significant protection of OGD-induced 
cell  toxicity compared to the OGD alone group 
(22.14±1.68 vs. 20.22±2.34%, respectively, P > 0.05). 
Inhibition of SC death with TMP was also confirmed by 
double-labeling with calcein-AM/EthD-I (Figure 3).
A LDH colorimetric assay was used to quantify cell 
death. As shown in Figure 4, LDH leakage significantly 
increased after OGD exposure compared to the normal 
control group (14.26±0.48%, P<0.05). Importantly, TMP 
(50, 100, and 200 μg/mL) significantly attenuated OGD-
induced cell death, which reduced the LDH release to 
51.50±5.17, 44.43±5.72, and 46.42±3.50%, respectively, 
compared to the OGD alone group (all P<0.05). However, 
treatment with 25μg/ml TMP (95.52±3.34%) provided 
no significant protection of OGD-induced cell death 
compared to the OGD alone group (P>0.05). In addition, 
no statistically significant difference was found between 
the OGD alone and vehicle control groups (98.70±6.33%, 
P>0.05).
Protective effects of TMP on SCs against OGD-
induced apoptosis
In order to verify whether TMP could protect cells 
from OGD-induced apoptotic death, further analyses 
using annexin V-FITC/PI staining were performed. 
The cell populations of annexin V+/PI− and annexin 
V+/PI+ were calculated as a representation of apoptotic 
cells, respectively, and the data were presented as the 
percentage of apoptotic cells. As shown in Figure 5, 
treatment of SCs with OGD significantly induced cell 
apoptosis compared to the normal control (23.83±6.59 
vs. 4.44±0.86%, respectively, P<0.05), and no statistically 
significant difference was found between the OGD alone 
and vehicle control groups (23.83±6.59 vs. 22.83±7.03%, 
respectively, P>0.05). Treatment with 25, 50, 100, and 
200 µg/mLTMP significantly attenuated OGD-induced 
apoptosis compared to the OGD alone group (17.60±5.73, 
11.43±2.48, 6.78±1.10, and 7.18±0.86 vs. 23.83±6.59%, 
respectively, all P<0.05).
Since the highest cell viability and lowest level 
of LDH release and percentage of apoptotic cells was 
detected in the 100 or 200 μg/mL TMP treatment groups, 
the 100μg/ml concentration was chosen for real-time PCR 
and Western blot analyses.
Real-time PCR and Western blot analyses
Real-time PCR analysis revealed a modulation of 
FIGURE 3 - Calcein-AM/EthD-I staining and quantitative 
evaluation. A: Normal control group; B: OGD alone group; C: 
Vehicle control group; D: 25 μg/mL TMP group; E: 50 μg/mL 
TMP group; F: 100 μg/mL TMP group; and G: 20.0 μg/mL TMP 
group. The magnification is 400x. The viability of Schwann 
cells was determined with the double-labeling fluorescence 
technique, whereby living cells, hydrolyzing calcein-AM by 
intracellular esterases, generate a green fluorescence. Dead cells 
are labeled with EthD-I, which interacts with DNA resulting 
in a red fluorescence of cell nuclei. The percentage of dead 
cells (EthD-I positive) within the total number of Schwann cell 
profiles in the respective culture was counted and expressed as 
mean ± SD. *P < 0.05 vs. normal control group. #P < 0.05 vs. 
cells exposed to OGD alone. &P < 0.05 vs. 50 μg/mL TMP group.
Tetramethylpyrazine protects Schwann cells from ischemia-like injury and increases cell survival in cold ischemic rat nerves 133
FIGURE 4 - LDH release assay. SC death was evaluated by LDH 
release into the culture medium. Data are expressed as the mean 
percentage of the maximal LDH released in the OGD alone 
group. Values are expressed as mean ± standard deviation (SD). 
*P<0.05 vs. normal control group. #P < 0.05 vs. cells exposed to 
OGD alone. &P < 0.05 vs. 50 μg/mL TMP group.
FIGURE 5 - TMP reduces OGD-induced apoptosis of SCs. A: 
Normal control group; B: OGD alone group; C: Vehicle control 
group; D: 25 μg/mL TMP group; E: 50 μg/mL TMP group; F: 
100 μg/mL TMP group; and G: 200 μg/mL TMP group. The 
percentage of apoptotic cells detected by annexin V-FITC/
PI staining and flow cytometry. The apoptotic cells included 
annexin V+/PI− and annexin V+/PI+ cells. Results are expressed 
as the mean ± SD of five independent experiments. *P < 0.05 
vs. normal control group. #P < 0.05 vs. cells exposed to OGD 
alone. &P < 0.05 vs. 25 μg/mL TMP group.
apoptosis-relevant genes in SCs exposed to OGD. As 
shown in Figure 6, the mRNA expression of Bax and 
caspase-3 genes was significantly increased 1.5-fold 
compared to the normal control (both P<0.05), whereas 
mRNA expression of Bcl-2 was downregulated by 
approximately 80% (P<0.05). No significant differences 
in the expression of Bax, Bcl-2, and caspase-3 genes 
were observed compared to the OGD alone and vehicle 
control groups (all P>0.05). Importantly, treatment with 
TMP inhibited the induction of caspase-3 and Bax genes 
expression, whereas expression of Bcl-2 was elevated 
compared to the OGD alone group (all P<0.05).
The results from Western blot analyses also 
proved that the expression of Bax increased, whereas 
Bcl-2 expression decreased after exposure to OGD. 
Moreover, the 32 kDa pro-enzyme form of caspase-3 
and its cleavage into the active 17 kDa isoform were 
both induced by OGD. However, treatment with 100 μg/
mL TMP significantly inhibited caspase-3 expression 
and activation, elevated Bcl-2 levels, and reduced Bax 
expression relative to the OGD alone group (Figure 
7). Taken together, these results clearly demonstrate 
that TMP can prevent OGD-induced apoptosis by 
upregulating anti-apoptotic Bcl-2 and downregulating 
the apoptotic markers Bax and caspase-3.
Study 2
Electron microscopy
Histological examination revealed a remarkable 
difference in the state of nerve segments from each group 
(Figure 8). In the group treated with 200-400 mg/mL 
TMP, there was some evidence of degenerative changes, 
but the basal lamina as well as the cytoplasmic membrane 
remained intact and SCs were present. In contrast, the 
group receiving 100mg/ml TMP, as well as the UWS 
control, had no detectable SCs.
Assessment of nerve graft viability
In order to verify whether TMP provided a protective 
effect for nerve segment viability, further analyses using 
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calcein-AM/EthD-I staining were performed. The fresh-
nerve fibers displayed an intense green fluorescence along 
their entire length with little red fluorescence. There was 
no clear difference in the confocal microscopic images 
between the 200, 300, and 400 mg/mL TMP treatment 
groups, and intense green fluorescence with dispersed red 
fluorescence was observed in most nerve fibers. In marked 
contrast, the 100 mg/mL TMP-nerve and UW-nerve 
groups displayed intense red fluorescence with little green 
staining, indicating that the fibers were dead (Figure 9).
Assessment of nerve graft apoptosis
Prolonged cold ischemic exposure for four weeks 
was highly associated with the presence of cell apoptosis 
in nerve segments preserved with UWS alone. The number 
of TUNEL-positive cells was dramatically higher in the 
UW-nerve group compared to the fresh-nerve group 
(12.43±1.62 vs. 1.71±0.49%, respectively, P<0.05). In 
contrast, TUNEL-positive cells were significantly lower 
in the TMP-treated nerve groups treated with 100, 200, 
300, and 400 mg/mL compared to the UW-nerve group 
control (7.57±0.98, 5.86±0.90, 6.00±0.82, and 5.57±0.79 
vs. 12.43±1.62%, respectively, all P<0.05; Figure 10). 
Therefore, these results indicate that adding TMP into 
UWS can reduce cell apoptosis in a concentration-
FIGURE 6 - Real-Time PCR analysis of the ratio of Bax, Bcl-2, 
and caspase-3 mRNA levels in SCs. The results were expressed 
as the mean ± SD. *P < 0.05 vs. normal control group. #P < 0.05 
vs. cells exposed to OGD alone.
FIGURE 7 - Representative immunoblot of Bax, Bcl-2, 
caspase-3, and cleaved caspase-3 proteins. A: Normal control 
group; B: OGD alone group; C: Vehicle control group; and D: 
100 μg/ml TMP group. The results were expressed as the mean 
± SD. *P < 0.05 vs. normal control group. #P < 0.05 vs. cells 
exposed to OGD alone.
FIGURE 8 - Electron microscopy of Fresh-, TMP-, and UW-
nerve cross-sections after four weeks of preservation. A: 
Fresh-nerve group; B: UW-nerve group; C-F: 100-400 mg/mL 
TMP-nerve group. SCs are preserved in the nerve segments 
from 200, 300, and 400 mg/mL TMP-nerve group, while the 
nerve segments stored for four weeks in 100 mg/ml TMP or 
UWS alone show myelin breakdown and an absence of SCs. 
SC nucleus (✩). Scale bars: 2 μm.
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FIGURE 9 - Confocal microscopy of Fresh-, TMP-, and UW-
nerve fibers stained with calcein-AM/EthD-I. A: Fresh-nerve 
group; B: UW-nerve group; C-F: 100-400 mg/mLTMP-nerve 
group. Fresh-nerve fibers present a typical uniform green 
calcein fluorescence with almost no detectable labeling of the 
SC nucleus by red EthD- I fluorescence. Nerve fibers from 
200, 300, and 400 mg/mL TMP-nerve groups display intense 
green fluorescence with dispersed red fluorescence, while the 
100 mg/mL TMP-nerve and UW-nerve groups have obvious red 
EthD-I fluorescence, demonstrating that SCs within these fibers 
are dead. Scale bars: 75 μm.
dependent manner in a cold ischemic nerve segment model 
after prolonged ischemia exposure for four weeks.
DISCUSSION
Ischemic injury can initiate a cascade of events that 
results in inflammation and cell death by apoptosis and 
necrosis (Faubel, Edelstein, 2005). Apoptosis is a type of 
cell death that occurs as a cascade of cellular machinery. 
It is believed that the ultimate vulnerability of cells to 
multiple apoptotic stimuli is influenced or determined 
by the Bcl-2 family (Yang, Korsmeyer, 1996), among 
FIGURE 10 - TUNEL-stained nerve sections obtained from each 
group. A: Fresh-nerve group; B: UW-nerve group; C-F: 100-
400 mg/mL TMP-nerve group. The magnification is 400x. The 
number of TUNEL-positive cells was counted in five random 
microscopic fields from each section. Data are expressed as the 
number of TUNEL-positive cells per field. Values are expressed 
as mean ± SD. *P < 0.05 vs. Fresh-nerve group. #P < 0.05 vs. 
UW-nerve group. &P < 0.05 vs. 100 mg/mL TMP-nerve group.
which the pro-apoptotic protein Bax plays a dominant 
role in initiating cell death. The translocation of Bax 
to the mitochondrial membrane may cause a loss of 
mitochondrial membrane potential and an increase of 
mitochondrial permeability, which consequently disrupts 
the integrity of the mitochondrial membrane, hastens 
the release of cytochrome c from the mitochondria, and 
leads to caspase-3 activation and ultimately apoptosis 
(Chinnaiyan et al., 1996; Condorelli et al., 1999). In 
contrast, the anti-apoptotic protein Bcl-2 of the Bcl-
2 family, which are potential inhibitors of apoptosis 
(Henshall et al., 2002; Creson et al., 2009), prevent the 
release of cytochrome c from mitochondria and caspase 
activation (Akhtar, Ness, Roth, 2004; Kuhn et al., 2005; 
Shacka, Roth, 2005) and can inhibit not only caspase-
dependent apoptosis, but also oxidant-induced apoptosis 
(Singh, Sharma, Singh, 2007). In addition, caspase-3 
is a key initiator and the “executioner caspase” in the 
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apoptotic pathway, mediates the cleavage of itself and 
other downstream caspases, and is centrally important in 
apoptotic cell death (Liu et al., 1997; Nunez et al., 1998). 
Therefore, Bax, Bcl-2, and caspase-3, which are all closely 
involved in the apoptotic pathway, were used as markers 
to determine the role of TMP in this study.
In Study 1, we demonstrated that TMP could 
partially alleviate OGD-induced injury of SCs in vitro. Our 
results from the MTT assay, calcein-AM/EthD-I staining, 
LDH release assay, and flow cytometry provide evidence 
that OGD induces a significant decrease in SC survival, 
whereas TMP preserves cell viability and inhibits OGD-
mediated apoptosis and LDH release in a dose-dependent 
manner. Moreover, we found that the maximal protective 
effect was observed at TMP concentrations of 100 or 
200 μg/mL. In addition, real-time PCR and Western blot 
analysis showed that TMP (100 μg/mL) attenuated the 
OGD-mediated upregulation of the pro-apoptotic protein 
Bax and downregulation of the anti-apoptotic protein Bcl-
2, as well as inhibited the activation of caspase-3. These 
data suggest that TMP may provide a protective effect 
against OGD-induced death of SCs in vitro, which may 
occur through the regulation of Bcl-2 and Bax expression 
and suppression of caspase-3 activation.
Previous studies have indicated that TMP has 
a remarkable neuroprotective effect during ischemic 
injury. Intraperitoneal administration of TMP was found 
to significantly protect the brain from ischemic insult, as 
shown by the reduction in infarction volume, neuronal 
loss, behavioral disturbance, and brain edema (Liao et al., 
2004; Kao et al., 2006). TMP may provide neuroprotection 
against ischemia brain injury by inducing thioredoxin 
transcription (Zhu et al., 2009) or by reducing nNOS 
expression (Xiao et al., 2010). In addition, some studies 
have reported that TMP has protective effects against 
cardiovascular diseases and ischemia-reperfusion damage 
in the kidney (Dai, Bache, 1985; Zhou et al., 2004; Chen 
et al., 2006; Feng et al., 2011). Moreover, several studies 
have shown that TMP has potent and effective anti-
apoptotic activity. TMP was found to attenuate apoptotic 
injury in rat cerebellar granule cells and the renal tubular 
cell line NRK-52E after iron-induced or adriamycin-
induced damage (Zhang et al., 2003; Cheng et al., 2006). 
The inhibition of H2O2-induced PC12 cell apoptosis 
by TMP may be related to the inhibition of caspase-3 
activation, suppression of cytochrome c release, and 
increase in the ratio of Bcl-2/Bax (Cheng et al., 2007). The 
anti-apoptosis activity of Ligusticum chuanxiong, which 
is the Chinese medicine where TMP originates, may also 
be mediated through a Protein Kinase A/cAMP Response 
Element-Binding (PKA/CREB)-dependent pathway in 
serum deprivation-induced PC12 cell apoptosis (Lin et 
al., 2007). During rat subarachnoid hemorrhage, TMP 
may ameliorate cerebral vasospasm by inhibiting the 
caspase-3-dependent apoptosis pathway (Gao et al., 2008). 
In spinal cord ischemia-reperfusion injury, alleviation 
of the damage and inhibition of apoptosis by TMP was 
linked to Bcl-2 and Bax expression regulation (Fan et al., 
2006). Chang et al., demonstrated that TMP may provide 
neuroprotective effects by inhibiting the activation of 
Hypoxia-Inducible Factor-1 alpha (HIF-1α), Tumor 
Necrosis Factor alpha (TNF-α), and caspase-3, resulting in 
a reduction in the infarct volume in ischemia-reperfusion 
brain injury (Chang et al., 2007). Taken together, these 
studies and our current findings indicate that TMP is 
an effective anti-apoptotic and ischemic factor that can 
attenuate ischemia-induced SC death. Based on these 
in vitro findings, we further investigated if TMP could 
attenuate ischemia injury and increase graft survival in a 
cold ischemic rat nerve model after prolonged ischemia 
exposure, which could be beneficial for peripheral nerve 
preservation.
Preservation techniques are essential for maintaining 
graft viability outside of the body prior to transplantation, 
and optimization of preservation solution components 
will ultimately help improving transplantation outcomes. 
A major focus of nerve allograft transplant research has 
been on preserving nerve tissues without compromising 
the viability and function of the transplanted nerve tissues. 
Ultimately, the goal would be to establish a nerve bank 
where an abundance of nerve graft materials of various sizes 
and from different HLA-type donors would be available 
immediately to recipients. To date, there is still no consensus 
on the optimal nerve graft preservation method that would 
allow for longer ischemic exposure during preservation 
without jeopardizing the viability of the graft.
UWS is an intracellular solution characterized by a 
relatively low sodium and high potassium concentration 
that is capable of maintaining organ quality over a 
long period of oxygen deprivation. Moreover, UWS 
can minimize hypothermic-induced cell swelling, 
prevent interstitial edema and intracellular acidosis, 
scavenge oxygen-free radicals, and provide substrates for 
regenerating high-energy phosphate compounds (Belzer, 
Southard, 1988). The solution is the gold standard for graft 
preservation and has been successfully used to preserve 
explanted liver, heart, and kidney prior to transplantation 
(Lopez-Andujar et al., 2009; George et al., 2011; 
Hoeger et al., 2011). Thus, we chose UWS as nerve graft 
preservation solution in this experiment. In addition, the 
method for preserving peripheral nerves in UWS at 4 °C 
is simple and does not require any specialized equipment.
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Previous studies have tried using UWS for nerve 
graft preservation in peripheral nerve allotransplantation 
(Levi et al., 1994; Evans et al., 1995). However, it has 
been found that while short storage intervals of less than 
one week in UWS alone resulted in peripheral nerve 
segments containing functioning SCs, the long-term 
preservation of peripheral nerve segments for more than 
three weeks caused a substantial loss of SCs (Levi et 
al., 1994). SCs outnumber other non-neuronal cells in 
the peripheral nerve and play an indispensable role in 
promoting axonal regeneration by providing surface cell 
adhesion molecules (such as N-CAM and Ng-CAM/L1), 
synthesizing basement membrane components containing 
extracellular matrix proteins (such as laminin and 
fibronectin), and producing several neurotrophic factors 
and receptors (Fu, Gordon, 1997; Siemionow, Brzezicki, 
2009). Most pretreatment methods, such as chemical 
treatment, irradiation, freezing, lyophilization, and freeze-
thawing could effectively reduce nerve graft antigenicity; 
however, nerve regeneration remains inferior to autografts. 
One problem has been acellularizing the graft (Song, 
Yang, Russell, 2009), and although short nerve deficits 
(less than 3 cm) can be bridged by acellular grafts, longer 
deficits may be more dependent upon the presence of 
donor-derived viable SCs (Hems, Glasby, 1992; Evans et 
al., 1995; Strauch et al., 1996; Song, Yang, Russell, 2009), 
because viable SCs are essential for successful axonal 
regeneration through longer deficits (Hall, 1986; Feneley, 
Fawcett, Keynes, 1991; Bunge, 1993). Furthermore, 
Blais, Grenier, Berthod and Sun et al. found that tissue-
engineered skin or acellular nerve allografts seeded with 
SCs could improve nerve regeneration (Blais, Grenier, 
Berthod, 2009; Sun et al., 2009). Therefore, sustaining 
donor-derived viable SCs of preserved nerve graft until 
the graft is repopulated with host SCs is a critical feature 
in determining the outcome of nerve regeneration for 
peripheral nerve allografts.
Ischemia, even at low temperatures, has been found 
to be associated with apoptosis (Turkmen et al., 2011) and 
may be partly responsible for the decrease in viable SCs 
during nerve graft preservation. Ischemia time has been 
shown to correlate significantly with apoptosis rate in 
human cadaveric renal transplants (Castaneda et al., 2003). 
Moreover, Jani et al. demonstrated that cold ischemia 
results in pro-apoptotic caspase-3, -2, -8, and -9 activation, 
as well as increased apoptosis and tubular brush-border 
injury in a model of non-donation after cardiac death 
(non-DCD) kidney preservation with UWS (Jani et al., 
2004). Recently, it was also found that cold ischemia 
activated caspase-3 and caused widespread tubular cell 
apoptosis in DCD kidneys (Jani et al., 2011). The addition 
of a caspase inhibitor to the preservation solution was 
found to effectively reduce apoptosis (Natori et al., 1999; 
Natori et al., 2003; Jani et al., 2004). It was also found that 
adding green tea polyphenols, which can protect tissues 
from ischemia, to UWS, resulted in sustaining never 
graft viability (Ikeguchi et al., 2003). Thus, these studies 
together with our finding that TMP can protect SCs from 
ischemic insult, led us to hypothesize that the addition of 
TMP to UWS may attenuate ischemia injury and increase 
graft survival after prolonged cold ischemic exposure.
In Study 2, we demonstrated that prolonged cold 
ischemic exposure for four weeks was highly associated 
with the absence of viable SCs and an increase in 
apoptosis in nerves preserved in UWS alone. However, 
the addition of TMP to the UWS increased graft survival 
and reduced cell apoptosis in a concentration-dependent 
manner, with the maximum protective effect observed at 
a TMP concentration equal to or greater than 200 mg/mL. 
Therefore, our results have shown that the addition of TMP 
(≥200 mg/mL) in UWS can improve the cell survival of 
nerve grafts even after prolonged cold ischemia exposure 
for four weeks, which indicated that peripheral nerves 
may be preserved in a TMP solution. However, the exact 
mechanism by which TMP maintains graft viability and 
blocks apoptosis in a cold ischemic nerve model will 
require further studies. In addition, several key questions 
require further exploration before TMP can be used for 
routine peripheral nerve storage. For example, additional 
studies are need to confirm that nerve grafts preserved in 
a TMP solution after prolonged cold ischemia exposure 
can indeed be beneficial in the repair of massive nerve 
deficits and functional regeneration of in vivo models. In 
addition, we will need to determine the maximum period 
of time that nerve grafts can be preserved in TMP without 
any loss in viability.
Taken together, the findings presented here 
demonstrate that TMP exerts anti-ischemic properties on 
OGD-induced primary cultured SC injury and apoptosis 
by abrogating the activation of caspase-3 and altering the 
expression of Bcl-2 and Bax. Moreover, the addition of 
TMP to UWS can improve the preservation properties 
of the solution for use in nerve grafts by maintaining 
graft survival and reducing apoptosis in a concentration-
dependant manner. Therefore, TMP may be useful in the 
preservation of nerve grafts for repairing deficits and 
improving regeneration.
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